Short answer
Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). New Phase 3 obexelimab data in IgG4-related disease, including open-label extension results.
Zenas BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- New Phase 3 obexelimab data in IgG4-related disease, including open-label extension results
- Clinical update potentially informs efficacy durability and development prospects
- Exhibit 99.1 contains the detailed results and supporting data
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 extension showed 12-month flare-free probability of 0.93, supporting sustained obexelimab activity in IgG4-RD
- Obexelimab reduced cumulative glucocorticoid toxicity versus placebo, GTI difference -11.4, p=0.021, strengthening steroid-sparing rationale
- Treatment-free vaccination window produced influenza seroimmunity in 6 of 7 participants and COVID-19 seroimmunity in 4 of 4
- No flares occurred during the 34.6-day average treatment-free window, supporting potential vaccination pauses
- Phase 2 SLE topline results expected in 4Q 2026, providing the next material clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zenas BioPharma, Inc. 8-K filings
Get the next ZBIO 8-K as it lands
Follow ZBIO for push alerts, or ask the research agent what this filing means.